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Biologics have revolutionized the field of clinical immunology and proven to be both 
effective and safe in common immune-mediated inflammatory diseases (IMIDs) such as 
rheumatoid arthritis, inflammatory bowel diseases, and various hematological disorders. 
However, in patients with rare, severe IMIDs failing on standard therapies, it is virtually 
impossible to conduct randomized controlled trials. Therefore, biologics are usually pre-
scribed off-label in these often severely ill patients. Unfortunately, off-label prescription 
is sometimes hampered in these diseases due to a lack of reimbursement that is often 
based on a presumed lack of evidence for effectiveness. In the present article, we will 
discuss that off-label prescription of biologics can be a good way to discover new treat-
ments for rare diseases. This will be illustrated using a case of multicentric Castleman’s 
disease, an immune-mediated lymphoproliferative disorder, in which off-label tocilizumab 
(humanized anti-IL-6 receptor blocking antibody) treatment resulted in remarkable clinical 
improvement. Furthermore, we will give recommendations for monitoring efficacy and 
safety of biologic treatment in rare IMIDs, including the use of registries. In conclusion, 
we put forward that innovative treatments for rare IMIDs can be discovered via off-label 
prescription of biologicals, provided that this is based on rational arguments including 
knowledge of the pathophysiology of the disease.
Keywords: giant lymph node hyperplasia, multicentric castleman’s disease, off-label use, interleukin-6, 
tocilizumab, biological products, registries
iNtrODUctiON
In patients with rare, severe immune-mediated inflammatory diseases (IMIDs), biologics are often 
the last treatment option when standard therapy with classical immunosuppressive drugs fails. 
However, clear guidelines on biologic prescription in these diseases are often lacking. A major reason 
is that proper randomized controlled trials (RCTs) are difficult to design due to the low prevalence, 
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heterogeneity of patients, and the severe medical condition of 
patients. Since RCTs are usually required for registration of therapy 
for a specific disease, physicians often prescribe biologics off-label 
in these diseases (1). Off-label prescription can be defined as the 
prescription of a drug for conditions other than current registered 
indications. This means that the drug is approved by either FDA 
or EMA for a certain disease, yet there is no definitive proof for the 
efficacy of the specific drug for other conditions. The physician’s 
decision to prescribe off-label in such cases is often based on the 
pathophysiology of the disease or shared symptoms with other 
diseases in which the biologic has proven to be effective. This is 
called rational prescription and may lead to innovative treatment 
options, especially in rare diseases. We will illustrate this in the 
present article by discussing the case of Castleman’s disease (CD) 
and interleukin (IL)-6 receptor blockade, including a case report 
of a patient who responded very well to this treatment strategy. 
In addition, we provide an overview of current new developments 
toward responsible off-label use of biologics in rare, severe, and 
therapy-refractory IMIDs.
cAstLeMAN’s DiseAse: cLiNicAL 
sYMPtOMs AND tHe rOLe OF iL-6
Castleman’s disease is a rare and relatively unknown lym-
phoproliferative disorder. It is characterized by polyclonal 
B-cell proliferation, usually associated with autoimmune and 
connective tissue symptoms, and often goes together with a pre-
existing autoimmune disorder, such as rheumatoid arthritis (RA), 
Sjögren’s syndrome, and systemic lupus erythematodes (SLE) (2).
Castleman’s disease can be divided into unicentric Castleman’s 
disease (UCD) and multicentric Castleman’s disease (MCD). In 
UCD, a single lymphoid region is involved, in contrary to the 
latter in which multiple lymphoid regions are involved (3). UCD 
usually causes complaints resulting from enlargement of one or 
more lymph nodes and mostly lacks systemic symptoms (2). 
Removal of the lymph node cures 90% of the patients without 
further complications (4). MCD, on the other hand, can cause 
“B symptoms” and signs such as anorexia, anemia, and low white 
blood cell counts (3). MCD has been associated with HIV infec-
tion, which is similar to MCD observed in non-HIV-infected 
patients, except for the high prevalence of pulmonary symptoms 
and strong association with Kaposi’s sarcoma. Interestingly, also 
HHV-8, a virus causing Kaposi’s sarcoma, is also associated with 
MCD (5). Both UCD and MCD are characterized by hypersecre-
tion of IL-6, most likely by germinal center B-cells in hyper-
plastic lymph nodes. Furthermore, a correlation between serum 
IL-6 levels and clinical symptoms of patients with CD was shown 
(6). IL-6 regulates T-cell function, acute phase reaction, and 
terminal B-cell differentiation (2). Overproduction of IL-6 can 
cause various symptoms, including fever and lymphadenopathy, 
and has been associated with autoimmune disorders, such as 
RA and juvenile idiopathic arthritis (JIA), as well as lymphoid 
malignancies (7). The prognosis for MCD is usually better when 
diagnosed early. Yet, early diagnosis can be very challenging 
because of the common manifestation of lymph node enlarge-
ment in patients with various autoimmune disorders. Moreover, 
diagnosing MCD can sometimes be hard, because symptoms are 
often not very specific. Nonetheless, CD should be suspected 
when a patient’s primary diagnosed disease, such as another 
lymphoproliferative disease or autoimmune disease is unusually 
hard to treat (8).
treAtMeNt OF cAstLeMAN’s DiseAse
Corticosteroids are given as standard therapy in CD, usually 
resulting in improvement of symptoms, normalization of 
laboratory parameters, and regression of lymphadenopathy (2, 
4). However, relapses are often seen after tapering the dose. Other 
treatment options are combination chemotherapy and the use of 
lenalidomide/thalidomine (4). Biologics have also been used in 
the treatment of CD. Rituximab (chimeric anti-CD20 monoclo-
nal antibody) may be effective, especially in CD patients with 
pre-existent autoimmune disease (9). Interestingly, long-term 
remission has also been reported after rituximab administra-
tion (2). Clinical improvement after rituximab treatment has 
been associated with reduced serum levels of pro-inflammatory 
cytokines, including IL-6 (10). The following case report illustrates 
the challenges in the treatment of MCD and the potential benefit 
of rational off-label prescription of biologics in rare IMIDs. In 
accordance with Dutch laws, the patient gave written informed 
consent to both the off-label treatment with tocilizumab and the 
use of his case for this manuscript.
cAse rePOrt
A 63-year-old male patient was referred with lymphadenopathy, 
limb pain, weight loss, and night sweats. Infectious causes and 
lymphoma were excluded. Eventually, he was diagnosed with 
MCD, based on clinical manifestations in combination with 
results of lymph node and bone marrow biopsies demonstrating 
polyclonal B-cell proliferation. HHV-8 and HIV tests were nega-
tive. After failing to respond to high-dose prednisolone treat-
ment, rituximab was administered, dosed in a cycle of 1000 mg 
intravenously twice every 6 months, which eventually led to a 
stable condition for 2 years. However, the disease recurred with 
extensive lymphadenopathy and strongly elevated erythrocyte 
sedimentation rate (ESR) levels. In addition, he experienced 
severe weight loss (10  kg), nausea, loss of appetite, increased 
muscle pain, and extreme fatigue, resulting in disability. Based 
on the important role of IL-6 in the biology of B-cells, elevated 
IL-6 levels in patients with CD, and case reports, tocilizumab 
(anti-IL-6 receptor antibody) treatment was initiated (600  mg 
biweekly intravenously) combined with methotrexate (7.5  mg 
weekly). This resulted in a marked decrease in C-reactive 
protein (CRP) and ESR levels, normalization of hemoglobin 
(Hb) (Figure  1) and albumin levels and remarkable clinical 
improvement (weight gain and improvement in overall physi-
cal condition). In addition, there was a significant reduction of 
the lymphadenopathy. Lowering the frequency of tocilizumab 
administration was not possible as this resulted in immediate 
flaring of the disease. Subsequent increased dosing induced 
remission again.
FigUre 1 | inflammatory parameters and hemoglobin levels in time. Red line indicates start tocilizumab therapy.
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iL-6 BLOcKADe iN cAstLeMAN’s 
DiseAse
As already mentioned, IL-6 overproduction is associated with 
the pathogenesis of CD and IL-6 signaling can be blocked by 
tocilizumab, a humanized monoclonal antibody directed against 
the human IL-6 receptor. Tocilizumab is used in the treatment 
of chronic inflammatory diseases in which IL-6 has been impli-
cated in the pathogenesis and exerts its effects by neutralizing 
the pro-inflammatory effects of IL-6/IL-6 receptor signaling. In 
addition, tocilizumab treatment may increase the proportion and 
function of regulatory T cells in the peripheral blood, as has been 
described in RA (11, 12).
Like most other biologics, the use of tocilizumab is associated 
with a moderately increased risk of infection. Furthermore, 
patients sometimes exhibit a transient hypercholesterolemia. 
Tocilizumab is an effective and safe officially approved treatment 
for RA and JIA. We describe the successful treatment of a patient 
with CD with tocilizumab. Over the past few years, several other 
reports have also described as a good outcome of IL-6 recep-
tor blockade in patients with CD. Nishimoto et  al. report an 
open-label study of 28 patients with MCD. Patients were treated 
biweekly with 8 mg/kg of tocilizumab for 16 weeks, resulting in 
improvement of symptoms, reduced acute phase reactants, and 
decreased need for corticosteroids (13). Interestingly, a recent 
paper reported persistent improvement of anemia in CD after the 
administration of tocilizumab. Twelve months after tocilizumab 
administration, iron-related parameters normalized and symp-
toms improved in all nine patients (14). This can be explained by 
the role of IL-6 as inducer of hepcidin, a principal regulator of 
iron homeostasis (15). Tocilizumab blocks the IL-6 receptor and 
indirectly downregulates hepcidin. This results in a decrease of 
iron storage and therefore an increase of serum iron available for 
Hb synthesis and erythrocyte production, leading to a normaliza-
tion of the anemia in MCD (2, 14).
As described here, tocilizumab can be very effective in 
patients with this condition who do not respond to conventional 
treatment (16). In Japan, these findings have led to the approval 
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and registration of tocilizumab for the treatment of CD (2, 16). 
However, in many other countries, including the Netherlands and 
the USA, tocilizumab has not been approved for the treatment of 
CD and is therefore often not reimbursed.
rAtiONAL PrescriPtiON OF BiOLOgics 
AND MONitOriNg OFF-LABeL Use
This case report illustrates that off-label prescription is sometimes 
the only option left after failure of all other possible treatments 
and can be very effective. Importantly, off-label prescription of 
biologics should preferably be “rational,” i.e., prescription of an 
approved drug proven to be safe and effective in a certain disease 
for another disease based on shared signs and symptoms or 
knowledge on the pathophysiology of the disease. The present 
case is a good example of rational prescription, as the initiation of 
tocilizumab treatment was mainly based on the important role of 
IL-6 in the pathophysiology of CD. Other examples of this are the 
use of anti-TNF biologics in TNF-driven diseases or the prescrip-
tion of IL-1 receptor antagonists in autoinflammatory diseases 
that are characterized by derailed IL-1-dependent intracellular 
processes (1).
Obviously, it is crucial to carefully monitor efficacy and safety 
of biologics that are prescribed off-label (1). This is not only 
important for individual patients but also for generating more 
evidence to eventually support reimbursement of novel off-label 
treatments for rare IMIDs; especially since healthcare authorities 
often decide that off-label prescription of these expensive drugs 
is not reimbursed due to “lack of evidence” for efficacy in rare 
IMIDs, which may prevent physicians from prescribing biologics 
in these patients. We therefore advocate improved monitoring 
and report ing off-label use of biologics through registries. In 
several countries, registries have been set up that have provided 
important information on safety and efficacy in a variety of 
conditions (17). For example, the RUBRIC registry (acronym 
for Rational Use of Biologics in Refractory Immune-mediated 
inflammatory diseases Consortium) is a web-based registry in the 
Netherlands aiming to identify and monitor all patients suffering 
from rare therapy-refractory IMIDs who are treated off-label 
with biologics (18). The information that is generated will be used 
to develop treatment protocols, which may guide physicians on 
off-label prescription of biologics and may help payers to make 
informed decisions about reimbursement.
cONcLUsiON
Off-label prescription of drugs is both legal and common and may 
give early access to new valuable treatments for patients, thereby 
adding to the innovation of clinical practice. This is especially the 
case in “orphan diseases” such as rare IMIDs, in which it is very 
difficult to conduct RCTs, but it also holds true for more com-
mon diseases as exemplified by infliximab (anti-TNF) treatment 
for refractory sarcoidosis. However, it is crucially important to 
consequently monitor efficacy and safety. We therefore advocate 
the use of registries, which will result in the collection of unbiased 
data that can be used to develop treatment guidelines for off-label 
prescription of biologics in individual rare IMIDs. Ultimately, this 
will lead to a more evidence-based and rational use of biologics 
in these diseases.
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